USFDA concludes inspection at Zydus’ LiqMeds in U.K. with four observations

The United States Food and Drug Administration completed an on‑site inspection of Zydus Lifesciences’ LiqMeds facility in the United Kingdom from November 9 through November 13. The inspection was part of the FDA’s routine oversight of foreign drug manufacturers that supply products to the United States market. Inspectors examined manufacturing records, quality‑control procedures, and compliance with current Good Manufacturing Practice (cGMP) requirements. The visit concluded with a formal report that listed four observations that the agency expects the company to address.

Zydus Lifesciences disclosed the outcome of the inspection in a regulatory filing to Indian stock exchanges, noting that the four observations related to documentation gaps, equipment calibration, and minor deviations in batch release processes. The company stated that it had already initiated corrective actions and would submit a detailed response to the FDA within the prescribed timeframe. By making the information public, Zydus aims to keep investors informed about potential regulatory risks and to demonstrate its commitment to transparency.

The inspection outcome is significant for the Indian pharmaceutical industry because many exporters rely on FDA approval to access the lucrative U.S. market. Any unresolved observations could delay product shipments, affect revenue, and raise questions about overall compliance standards. For investors, the filing provides an early signal of possible operational challenges, while regulators may use the findings to guide future oversight of Indian manufacturers abroad. Maintaining strong quality systems remains essential for sustaining export growth and protecting public health.